Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a malignancy where the first-generation drug ibrutinib (Imbruvica ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to ...

Long-term results of a phase 3 trial show that early rituximab monotherapy significantly delays the need for new treatment in ...

If you have follicular lymphoma, there are many treatments available that vary depending on the stage of your cancer. Understanding your stage is key to making your treatment decisions.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.